9
项与 人胰岛素生物类似药(Wockhardt Ltd.) 相关的临床试验A RANDOMIZED, SINGLE CENTER, DOUBLE BLIND, TWO TREATMENT, TWO-PERIOD, CROSSOVER GLUCOSE CLAMP STUDY TO TEST FOR BIOEQUIVALENCE BETWEEN WOCKHARDTâ??S WOSULIN® 30/70 (100 IU/mL) {BIPHASIC ISOPHANE INSULIN INJECTION/ 70% HUMAN INSULIN ISOPHANE SUSPENSION AND 30% HUMAN INSULIN INJECTION (r-DNA ORIGIN)} AND HUMULIN® 70/30 (100 U/mL) {70% HUMAN INSULIN ISOPHANE SUSPENSION AND 30% HUMAN INSULIN INJECTION (rDNA origin)} IN HEALTHY SUBJECTS. - Clamp Study
A RANDOMIZED, SINGLE CENTER, DOUBLE BLIND, TWO TREATMENT, TWO-SEQUENCE, TWO PERIOD, CROSSOVER GLUCOSE CLAMP STUDY TO TEST FOR BIOEQUIVALENCE BETWEEN WOCKHARDTâ??S WOSULIN® N (100 IU/mL) {ISOPHANE INSULIN HUMAN, SUSPENSION, r-DNA ORIGIN} AND HUMULIN® N (100 U/mL) {HUMAN INSULIN (r-DNA ORIGIN) ISOPHANE SUSPENSION}, IN HEALTHY SUBJECTS. - Clamp Study
An Open Label, Randomized, comparison of the Immunogenicity and Safety of Wockhardts Human Insulin Basal Bolus Regimen {Intensified Conventional Insulin Therapy with Soluble Insulin and Isophane Insulin (Wosulin R, Wosulin N and Wosulin 70/30)} with the Novo Nordisk?s yeast based Human Insulin Basal Bolus Regimens, marketed in United States (Novolin® R, Novolin® N and Novolin® 70/30) in Type 1 Diabetics.
100 项与 人胰岛素生物类似药(Wockhardt Ltd.) 相关的临床结果
100 项与 人胰岛素生物类似药(Wockhardt Ltd.) 相关的转化医学
100 项与 人胰岛素生物类似药(Wockhardt Ltd.) 相关的专利(医药)
100 项与 人胰岛素生物类似药(Wockhardt Ltd.) 相关的药物交易